Benitec Biopharma (BNTC) Expected to Announce Earnings on Friday

Benitec Biopharma (NASDAQ:BNTC) is expected to issue its Q2 2026 results before the market opens on Friday, February 13th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, February 20, 2026 at 4:00 PM ET.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings results on Friday, November 14th. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.13. On average, analysts expect Benitec Biopharma to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Benitec Biopharma Stock Performance

Benitec Biopharma stock opened at $11.65 on Thursday. Benitec Biopharma has a fifty-two week low of $9.70 and a fifty-two week high of $17.15. The stock has a market cap of $399.13 million, a P/E ratio of -9.63 and a beta of 0.26. The firm’s fifty day moving average price is $12.39 and its 200-day moving average price is $13.17.

Insider Activity

In other Benitec Biopharma news, Director Suvretta Capital Management, L acquired 77,387 shares of the business’s stock in a transaction dated Monday, December 29th. The shares were purchased at an average cost of $13.44 per share, for a total transaction of $1,040,081.28. Following the transaction, the director owned 9,700,195 shares in the company, valued at $130,370,620.80. This represents a 0.80% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders bought 190,364 shares of company stock valued at $2,442,105 over the last quarter. 4.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its stake in Benitec Biopharma by 44.5% during the third quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 904 shares in the last quarter. Russell Investments Group Ltd. bought a new position in shares of Benitec Biopharma during the third quarter valued at $79,000. JPMorgan Chase & Co. bought a new position in Benitec Biopharma in the 2nd quarter worth about $80,000. Bank of America Corp DE grew its holdings in shares of Benitec Biopharma by 2,255.8% during the second quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 6,587 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Benitec Biopharma in the 2nd quarter worth approximately $93,000. 52.19% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Zacks Research raised Benitec Biopharma from a “strong sell” rating to a “hold” rating in a report on Friday, November 14th. Citigroup reissued an “outperform” rating on shares of Benitec Biopharma in a report on Tuesday, November 4th. JMP Securities set a $22.00 price target on shares of Benitec Biopharma in a report on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Benitec Biopharma in a research report on Wednesday, January 21st. Finally, Citizens Jmp raised their price target on Benitec Biopharma from $20.00 to $22.00 and gave the company a “market outperform” rating in a research report on Tuesday, November 4th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.25.

Benitec Biopharma Company Profile

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.